FDA Reviewing Evidence That Morning-After Pill Doesn’t Work in Women Weighing Over 176 Pounds

<a href="http://www.flickr.com/photos/22069127@N03/2695489692/">VixyView</a>/Flickr

Monday morning, Mother Jones reported that the European manufacturer of an emergency contraceptive pill identical to Plan B, also known as the morning-after pill, will warn women that the drug is completely ineffective in women weighing more than 176 pounds, and begins to lose effectiveness in women weighing more than 165 pounds. HRA Pharma, which makes the European drug, Norlevo, asked European regulators for permission to change the drug’s labeling after reviewing its own clinical data and scientific research from 2011 which showed emergency contraceptives are prone to fail in women with higher body mass indexes.

Now the Food and Drug Administration has responded to this story, telling Mother Jones that FDA officials are weighing whether pharmaceutical companies that sell similar emergency contraceptive pills in the US must change their labeling. Many popular morning-after pills sold in the US—including one-pill emergency contraceptives Plan B One-Step, Next Choice One Dose, and My Way, as well as a number of generic two-pill emergency contraceptives—are chemically identical to Norlevo, which also uses the chemical compound levonorgestrel to prevent pregnancy after sex. 

“The FDA is currently reviewing the available and related scientific information on this issue, including the publication upon which the Norlevo labeling change was based,” FDA spokeswoman Erica Jefferson writes in an email. “The agency will then determine what, if any, labeling changes to approved emergency contraceptives are warranted.”

Jefferson declined to say when the FDA began its review. If FDA officials feel they have sufficient data to justify a change to product information, the FDA can order companies to update their labels. Jefferson adds that US drug companies have a legal obligation to alert the FDA if new information makes their existing labeling inaccurate.

“Both brand and generic drug manufacturers have an ongoing obligation to ensure their product labeling is accurate and up to date,” Jefferson writes. “When new information becomes available that causes information in drug product labeling to be inaccurate, both brand and generic drug application holders must take steps to change the content of their product labeling.”

The FDA requires generic drugmakers to display the same product information that appears on brand-name drugs, if a brand name exists. Since Plan B One-Step is a brand name, the makers of My Way and Next Choice One Dose cannot update their packaging information unless the FDA acts or Teva Pharmaceutical Industries, the exclusive manufacturer of Plan B One-Step, changes its labels first.

However, any manufacturer can submit information for the FDA to review, and Jefferson adds that the FDA can also request information from Teva “as appropriate.”

When the FDA approved Plan B for sale in the US, it did not assess the effects of weight on the drug.

An HRA Pharma spokeswoman told Mother Jones that the company did its own review of clinical data before changing Norlevo’s labels. Anna Glasier, the professor of obstetrics and gynecology at the University of Edinburgh who wrote the study that prompted HRA Pharma’s review, told CNN that based on her research alone, she would still recommend these pills for heavier women.

“You are probably better to take [levonorgestrel emergency contraceptives] after unprotected sex than just to leave it to chance even if you are obese,” she said. Ella, an emergency contraceptive that Glasier found to be more effective in heavier women, is only available in the US by prescription.

Neither Actavis nor Gavis, which manufacture generic versions of Plan B One-Step, replied to questions about changing their labels last week. A Teva spokeswoman declined to comment. Norlevo is not approved for sale in the US.

“When we became aware that there appeared to be an impact on efficacy (linked to weight), we felt it was our ethical duty as a drug manufacturer to report it and be transparent,” Erin Gainer, the CEO of HRA Pharma, told New York Daily News on Monday.


as we head into 2020 is whether politics and media will be a billionaires’ game, or a playing field where the rest of us have a shot. That's what Mother Jones CEO Monika Bauerlein tackles in her annual December column—"Billionaires Are Not the Answer"—about the state of journalism and our plans for the year ahead.

We can't afford to let independent reporting depend on the goodwill of the superrich: Please help Mother Jones build an alternative to oligarchy that is funded by and answerable to its readers. Please join us with a tax-deductible, year-end donation so we can keep going after the big stories without fear, favor, or false equivalency.


as we head into 2020 is whether politics and media will be a billionaires’ game, or a playing field where the rest of us have a shot.

Please read our annual column about the state of journalism and Mother Jones' plans for the year ahead, and help us build an alternative to oligarchy by supporting our people-powered journalism with a year-end gift today.

We Recommend


Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.


Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.


We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.